Skip to main content
JAMA Network logoLink to JAMA Network
. 2023 Oct 26;330(19):1915. doi: 10.1001/jama.2023.22757

Error in Table

PMCID: PMC10603572  PMID: 37883095

The Original Investigation titled “Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial,”1 published online October 3, 2023, was corrected to fix an error in Table 2 in which the values for change from baseline to week 52 for hemoglobin A1c and body weight were inadvertently flipped for the 15-mg and 5-mg groups. This article was corrected online.

Reference

  • 1.Rosentock J, Frías JP, Rodbard HW, et al. Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial. JAMA. Published online October 3, 2023. doi: 10.1001/jama.2023.20294 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from JAMA are provided here courtesy of American Medical Association

RESOURCES